Inhibitors of cathepsin G: a patent review (2005 to present)
Paulina Kosikowska1, Adam Lesner
1University of Gdansk, Department of Bioorganic Chemistry , Wita Stwosza 63, 80-952 Gdansk , Poland +48585235095 ; +48585235472 ; alesner@chem.univ.gda.pl.
Insights
Cathepsin G (CatG) inhibitors show therapeutic promise, particularly natural compounds like boswellic acids. Further research is needed to develop stable, clinically effective CatG-targeting drugs.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Discovery
Background:
- Cathepsin G (CatG) is a neutrophil proteinase with dual specificity, implicated in inflammatory diseases like COPD and rheumatoid arthritis.
- Its enzymatic activity is difficult to control, making it a therapeutic target, though no drugs are currently marketed.
- CatG's role in disease pathophysiology drives interest in developing specific inhibitors.
Purpose of the Study:
- To analyze the therapeutic potential of Cathepsin G inhibitors.
- To review patent applications and academic literature on CatG inhibitors from 1991-2012.
- To identify promising inhibitor classes and future research directions.
Main Methods:
- Comprehensive review of patent applications and academic publications.
- Analysis of disclosed CatG inhibitors within a specific time frame (1991-2012).
- Inclusion of select inhibitors from academic articles outside patent disclosures.
Main Results:
- Several CatG inhibitor classes show promise, including beta-ketophosphonic acids, aminoalkylphosphonic esters, and boswellic acids (BAs).
- Analogues of natural compounds, specifically peptidic and BA derivatives, appear most promising.
- No clinical disposition data is available for any identified CatG inhibitors.
Conclusions:
- Boswellic acid derivatives and other natural product analogues represent promising avenues for CatG inhibitor development.
- Significant work remains in designing stable, pharmacologically active compounds for specific in vivo CatG regulation.
- The lack of clinical data highlights the need for further research into the clinical efficacy and safety of CatG inhibitors.
Introduction:
Cathepsin G (CatG) is a neutral proteinase originating from human neutrophils. It displays a unique dual specificity (trypsin- and chymotrypsin-like); thus, its enzymatic activity is difficult to control. CatG is involved in the pathophysiology of several serious human diseases, such as chronic obstructive pulmonary disease (COPD), Crohn's disease, rheumatoid arthritis, cystic fibrosis and other conditions clinically manifested by excessive inflammatory reactions. For mentioned reasons, CatG was considered as good molecular target for the development of novel drugs. However, none of them have yet entered the market as novel therapeutic agents.
Areas Covered:
This article presents an in-depth and detailed analysis of the therapeutic potential of CatG inhibitors based on a review of patent applications and academic publishing disclosed in patents and patent applications (1991 - 2012), with several exceptions for inhibitors retrieved from academic articles.
Expert Opinion:
Among the discussed inhibitors of CatG, examples corresponding to derivatives of β-ketophosphonic acids, aminoalkylphosphonic esters and boswellic acids (BAs) could be regarded as the most promising. The most promising one seems to be analogues of compounds of Nature's origin (peptidic and BA derivates). Nevertheless, nothing is currently known about the clinical disposition of any of the CatG inhibitors discovered so far. This latter point suggests that there is still a lot of work to do in the design of stable, pharmacologically active compounds able to specifically regulate the in vivo activity of cathepsin G.
Related Concept Videos
GTPases and their Regulation
Large G-proteins, also known...
Enzyme Inhibition
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
Inhibition of Cdk Activity
ATP Synthase: Mechanism
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...


